US Broker Ratings

Recursion Pharmaceuticals (RXRX): Uncovering a 38% Potential Upside in Biotech Innovation

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a prominent player in the rapidly evolving biotechnology sector, leveraging cutting-edge technological advancements to redefine drug discovery. Headquartered in Salt..

Kiniksa Pharmaceuticals, Ltd. (KNSA) Stock Analysis: Exploring a 25% Upside with Strong Buy Ratings

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) is turning heads in the healthcare sector with its promising pipeline of treatments for diseases with unmet needs, particularly in the..

Travere Therapeutics, Inc. (TVTX): Investor Outlook Reveals 133% Potential Upside

Travere Therapeutics, Inc. (NASDAQ: TVTX) has captured investor attention with its impressive potential upside of 133.30%, driven by its focused endeavors in addressing rare kidney and..

Vera Therapeutics, Inc. (VERA) Stock Analysis: Eyeing a 192% Potential Upside with Strong Buy Ratings

Investors looking for opportunities in the biotechnology sector may want to keep a close watch on Vera Therapeutics, Inc. (VERA). As a clinical-stage biotech firm, Vera..

Privia Health Group, Inc. (PRVA) Stock Analysis: Unveiling a 30% Upside Potential

Privia Health Group, Inc. (PRVA), a compelling player in the healthcare sector, operates as a national physician-enablement company in the United States. With a market capitalization..

Celldex Therapeutics, Inc. (CLDX): Investor Outlook Reveals Stunning 176% Potential Upside

Celldex Therapeutics, Inc. (NASDAQ: CLDX), a cutting-edge biopharmaceutical company headquartered in Hampton, New Jersey, is making waves in the biotechnology sector. Specializing in the development of..

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: A 46.47% Upside Potential Amidst Strong Revenue Growth

BioCryst Pharmaceuticals, Inc. (BCRX), a prominent player in the healthcare sector, focuses on developing innovative treatments for rare diseases. With a current market capitalization of $2.32..

Dynavax Technologies Corporation (DVAX) Stock Analysis: Exploring a 126% Potential Upside in the Biopharmaceutical Sector

Dynavax Technologies Corporation (NASDAQ: DVAX), a prominent player in the healthcare sector, has caught the attention of investors with its ambitious vaccine development pipeline and a..

Disc Medicine, Inc. (IRON): Investor Outlook Highlights a Potential 92.92% Upside

Disc Medicine, Inc. (NASDAQ: IRON) is making waves in the biotechnology sector with its innovative approach to treating serious hematologic diseases. As a clinical-stage biopharmaceutical company,..

Janux Therapeutics, Inc. (JANX) Investor Outlook: Exploring a 224% Potential Upside in Cutting-Edge Cancer Therapies

Janux Therapeutics, Inc. (NASDAQ: JANX), a pioneering player in the biotechnology sector, has captured the attention of investors with its promising pipeline of cancer immunotherapies. With..

Twist Bioscience Corporation (TWST) Investor Outlook: Navigating Growth Potential Amidst Challenging Metrics

Twist Bioscience Corporation (NASDAQ: TWST), a prominent player in the Healthcare sector, particularly within the Diagnostics & Research industry, continues to captivate investors with its innovative..

SS Innovations International (SSII) Stock Analysis: Navigating the Highs and Lows of a Promising Medical Device Innovator

SS Innovations International, Inc. (SSII) is a burgeoning player in the healthcare sector, particularly within the medical devices industry. Headquartered in Gurugram, India, the company is..

PACS Group, Inc. (PACS) Stock Analysis: A Healthcare Gem with 241% Potential Upside

For investors with an eye for opportunity in the healthcare sector, PACS Group, Inc. (PACS) presents an intriguing proposition. Operating within the medical care facilities industry,..

Clover Health Investments (CLOV): Investor Outlook with a 57% Potential Upside

Clover Health Investments, Corp (NASDAQ: CLOV) is capturing investor attention with a substantial potential upside of 57.30%, according to recent analyst ratings. Positioned within the healthcare..

Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis: Exploring a 53.64% Upside Potential

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a biotech entity focused on pioneering therapeutics in the realm of cellular metabolism, is capturing investor attention with its promising portfolio..

Evotec SE (EVO) Stock Analysis: Exploring the 59.77% Potential Upside for Innovative Drug Discovery

Evotec SE (EVO) is at the forefront of the drug discovery and development sector, serving as a key partner to the pharmaceutical and biotechnology industries worldwide...

Merus N.V. (MRUS) Stock Analysis: Exploring 63.66% Potential Upside and Strong Buy Ratings

Merus N.V. (NASDAQ: MRUS), a Netherlands-based biotechnology enterprise, has been capturing investor attention with an impressive potential upside of 63.66% according to analyst forecasts. This clinical-stage..

GeneDx Holdings Corp. (WGS) Stock Analysis: Unveiling a Potential 31% Upside in Genomic Diagnostics

GeneDx Holdings Corp. (NASDAQ: WGS) stands out in the healthcare sector as a pioneering entity in the Diagnostics & Research industry. Based in Stamford, Connecticut, the..

Apogee Therapeutics, Inc. (APGE) Stock Analysis: A Biotech Powerhouse with a 133% Upside Potential

Apogee Therapeutics, Inc. (NASDAQ: APGE) has emerged as a noteworthy contender in the biotechnology sector, with its innovative approach to treating inflammatory and immunology disorders. Despite..

HUTCHMED (HCM) Stock Analysis: Exploring a 60% Upside in the Healthcare Sector

HUTCHMED (China) Limited (HCM) is carving out a prominent niche in the healthcare sector, focusing on pioneering therapies for cancer and immunological diseases. With a market..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds